Horizon Kinetics Asset Management LLC grew its position in shares of Royalty Pharma PLC (NASDAQ:RPRX – Free Report) by 2.4% during the third quarter, HoldingsChannel.com reports. The firm owned 353,191 shares of the biopharmaceutical company’s stock after purchasing an additional 8,330 shares during the period. Horizon Kinetics Asset Management LLC’s holdings in Royalty Pharma were worth $20,612,000 at the end of the most recent quarter.
A number of other hedge funds have also recently made changes to their positions in RPRX. Barrow Hanley Mewhinney & Strauss LLC increased its stake in shares of Royalty Pharma by 1.3% in the third quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 271,112 shares of the biopharmaceutical company’s stock valued at $15,822,000 after buying an additional 3,558 shares during the period. Sumitomo Life Insurance Co. raised its holdings in Royalty Pharma by 19.4% in the 3rd quarter. Sumitomo Life Insurance Co. now owns 41,258 shares of the biopharmaceutical company’s stock valued at $2,408,000 after buying an additional 6,707 shares during the last quarter. Edmond DE Rothschild Holding S.A. boosted its position in Royalty Pharma by 19.1% during the 3rd quarter. Edmond DE Rothschild Holding S.A. now owns 15,460 shares of the biopharmaceutical company’s stock worth $902,000 after buying an additional 2,483 shares during the period. Private Advisor Group LLC boosted its position in Royalty Pharma by 44.2% during the 3rd quarter. Private Advisor Group LLC now owns 13,232 shares of the biopharmaceutical company’s stock worth $772,000 after buying an additional 4,053 shares during the period. Finally, Ieq Capital LLC acquired a new stake in Royalty Pharma during the 3rd quarter worth approximately $4,837,000. 54.35% of the stock is owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
RPRX has been the topic of a number of research reports. JPMorgan Chase & Co. boosted their target price on shares of Royalty Pharma from $58.00 to $62.00 and gave the stock an “overweight” rating in a report on Friday, August 7th. Morgan Stanley raised their price target on shares of Royalty Pharma from $65.00 to $67.00 and gave the company an “overweight” rating in a research note on Wednesday, October 7th. Bank of America reaffirmed a “buy” rating on shares of Royalty Pharma in a research note on Wednesday, August 5th. Zacks Research upgraded shares of Royalty Pharma from a “hold” rating to a “strong-buy” rating in a report on Wednesday, November 11th. Finally, Wall Street Zen raised shares of Royalty Pharma from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 14th. One analyst has rated the stock with a Strong Buy rating and eight have given a Buy rating to the stock. According to data from MarketBeat, Royalty Pharma currently has a consensus rating of “Buy” and a consensus price target of $65.00.
View Our Latest Stock Analysis on Royalty Pharma
Royalty Pharma Trading Up 1.1%
Shares of RPRX stock opened at $68.47 on Friday. The company has a market cap of $39.28 billion, a P/E ratio of 57.06, a PEG ratio of 1.36 and a beta of 0.37. The stock has a 50 day simple moving average of $62.31 and a two-hundred day simple moving average of $55.20. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.29 and a current ratio of 1.29. Royalty Pharma PLC has a fifty-two week low of $37.31 and a fifty-two week high of $70.37.
Royalty Pharma Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be given a dividend of $0.2350 per share. The ex-dividend date of this dividend is Friday, November 13th. This represents a $0.94 annualized dividend and a dividend yield of 1.4%. Royalty Pharma’s dividend payout ratio (DPR) is 78.33%.
Insider Activity
In related news, EVP Marshall Urist sold 4,126 shares of the business’s stock in a transaction on Monday, October 5th. The shares were sold at an average price of $57.10, for a total transaction of $235,594.60. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Terrance Coyne sold 232,536 shares of the stock in a transaction on Monday, November 16th. The stock was sold at an average price of $68.87, for a total transaction of $16,014,754.32. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 440,788 shares of company stock worth $29,157,162 in the last quarter. 18.84% of the stock is owned by corporate insiders.
Royalty Pharma Profile
Royalty Pharma plc is a biopharmaceutical royalty company that provides funding to companies and inventors in exchange for royalty interests in medicines. It acquires existing royalties and helps finance drug development and commercialization through royalty-based transactions and other forms of funding. The company’s portfolio includes royalty interests in medicines across a range of therapeutic areas, spanning both approved treatments and products in development. Royalty Pharma generally earns revenue when these medicines are sold; it does not operate as a conventional drug manufacturer or commercialize medicines itself.
Featured Stories
- Five stocks we like better than Royalty Pharma
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
- MarketBeat Week in Review – 11/16 – 11/20
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
Want to see what other hedge funds are holding RPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Royalty Pharma PLC (NASDAQ:RPRX – Free Report).
Receive News & Ratings for Royalty Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Royalty Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
